Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti–PD1/PDL1 Clinical Trials

IMPORTANCE: Anti–programmed death 1 and anti–programmed death ligand 1 (anti–PD1/PDL1) immune checkpoint blockade (ICB) constitutes the therapeutic backbone for multiple malignant neoplasms. People living with HIV (PLWH) have routinely been excluded from ICB clinical trials, thus inhibiting broad im...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA Netw Open
Главные авторы: Reuss, Joshua E., Stern, Diana, Foster, Jared C., Ramaswami, Ramya, Lurain, Kathryn, Chen, Helen X., Streicher, Howard, Kem, Ravie, Little, Richard F., Sharon, Elad
Формат: Artigo
Язык:Inglês
Опубликовано: American Medical Association 2020
Предметы:
Original Investigation
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7709086/
https://ncbi.nlm.nih.gov/pubmed/33258905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.27110
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы